Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma

Approximately 60% of patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) are curable with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemoimmunotherapy. Epratuzumab (E) is an unlabeled anti-CD22 monoclonal antibody with efficacy in relapsed DLBCL. Th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Micallef, Ivana N. M., Maurer, Matthew J., Wiseman, Gregory A., Nikcevich, Daniel A., Kurtin, Paul J., Cannon, Michael W., Perez, Domingo G., Soori, Gamini S., Link, Brian K., Habermann, Thomas M., Witzig, Thomas E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2011
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3204728/
https://ncbi.nlm.nih.gov/pubmed/21673350
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-02-336990
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados